Provided by Tiger Trade Technology Pte. Ltd.

Haemonetics

108.92
+1.321.23%
Volume:242.22K
Turnover:26.53M
Market Cap:4.95B
PE:53.13
High:110.45
Open:107.81
Low:107.60
Close:107.60
52wk High:110.45
52wk Low:47.32
Shares:45.45M
Float Shares:44.60M
Volume Ratio:0.74
T/O Rate:0.54%
Dividend:- -
Dividend Rate:- -
EPS(TTM):2.05
EPS(LYR):2.05
ROE:11.20%
ROA:6.60%
PB:5.91
PE(LYR):53.13

Loading ...

Haemonetics price target lowered to $67 from $72 at Baird

TIPRANKS
·
May 09

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Haemonetics (HAE), Scholar Rock Holding (SRRK) and Ocugen (OCGN)

TIPRANKS
·
May 08

Stock Track | Haemonetics Soars 8.22% in Pre-market on Strong Q4 Earnings Beat and Upbeat Fiscal 2027 Guidance

Stock Track
·
May 07

Earnings Flash (HAE) Haemonetics Posts Fiscal Q4 Net Revenue $346.4M, vs. FactSet Est of $336.8M

MT Newswires Live
·
May 07

Haemonetics Corp Q4 REV View $336.9 Mln -- Lseg Ibes Data

THOMSON REUTERS
·
May 07

Haemonetics Corp - Fiscal 2027 Guidance Reported Revenue 4% - 7% - SEC Filing

THOMSON REUTERS
·
May 07

Haemonetics Corp -Fiscal 2027 Guidance Adjusted Earnings per Diluted Share Is Comparable to Revenue Growth- SEC Filing

THOMSON REUTERS
·
May 07

Haemonetics Q4 Adj. EPS $1.29 Beats $1.27 Estimate, Sales $346.351M Beat $336.862M Estimate

Benzinga Earnings
·
May 07

Haemonetics Q4 Revenue USD 346.4 Million VS. Ibes Estimate USD 336.9 Million

THOMSON REUTERS
·
May 07

Haemonetics Outlook FY Organic Growth 3-6%

THOMSON REUTERS
·
May 07

Haemonetics Q4 EPS USD -0.44

THOMSON REUTERS
·
May 07

Haemonetics Q4 FY26 swings to loss of ($0.44) per share; revenue rises 4.8% to $346.4 million

Reuters
·
May 07

Press Release: Haemonetics Corporation Announces Fourth Quarter Fiscal 2026 Financial Results Available on Investor Relations Website

Dow Jones
·
May 07

Haemonetics CEO Simon joins Bank of America Healthcare Conference fireside chat

Reuters
·
May 05

BioCryst Announces European Licensing Agreement with Irish Affiliate of Neopharmed Gentili for Navenibart in Hereditary Angioedema

GlobeNewswire
·
May 04

Haemonetics Announces Upcoming Departure of Longtime Board Director

TIPRANKS
·
May 02

Haemonetics director Charles Dockendorff to step down from board at annual meeting

Reuters
·
May 02

Earning Preview: Haemonetics this quarter’s revenue is expected to increase by 2.27%, and institutional views are bullish

Earnings Agent
·
May 01

Why Intellia Therapeutics (NTLA) Is Down 13.8% After Positive Phase 3 HAE Gene-Editing Results And FDA Filing

Simply Wall St.
·
Apr 29

Intellia Therapeutics Reports Positive Phase 3 Results in Hereditary Angioedema, Marking a Global First for In Vivo Gene Editing

GlobeNewswire
·
Apr 27